TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Participant must be younger than 12 years of age, at the time of signing the informed consent.~* Severe hemophilia A defined as \<1 international units per deciliter (IU/dL) (\<1 percent \[%\]) endogenous Factor VIII (FVIII) as documented either by central laboratory testing at Screening or in historical medical records from a clinical laboratory demonstrating \<1% FVIII coagulant activity (FVIII:C) or a documented genotype known to produce severe hemophilia A.~* Previous treatment for hemophilia A (prophylaxis or on-demand) with any recombinant and/or plasma-derived FVIII, or cryoprecipitate for at least 150 exposure days (EDs) for participants aged 6 to \<12 years and above 50 EDs for participants aged \<6 years.~* Weight above or equal to 10 kg.~Exclusion criteria:~* History of hypersensitivity or anaphylaxis associated with any FVIII product.~* History of a positive inhibitor (to FVIII) test defined as greater than or equal to (\>=) 0.6 Bethesda units (BU/mL), or any value greater than or equal to the lower sensitivity cut-off for laboratories with cut-offs for inhibitor detection between 0.7 and 1.0 BU/mL, or clinical signs or symptoms of decreased response to FVIII administrations. Family history of inhibitors would not exclude the participant.~* Positive inhibitor test result, defined as \>=0.6 BU/mL at Screening.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: MALE
- Minimum Age: None
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- BIVV001: Participants aged <6 Years (Type: EXPERIMENTAL): Participants aged less than (\<) 6 years received BIVV001 at a dose of 50 international units per kilogram (IU/kg) intravenous (IV) injection once-weekly (QW) prophylaxis for 52 weeks.
- BIVV001: Participants aged 6 to <12 Years (Type: EXPERIMENTAL): Participants aged 6 to \<12 years received BIVV001 at a dose of 50 IU/kg IV injection QW prophylaxis for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Molecular diagnosis of NALP3 mutations and clinical picture resembling Muckle-Wells Syndrome.~* Muckle-Wells Syndrome patients who participated in the CACZ885A2102 study, will have the option to participate in this study upon disease flare~* Muckle-Wells Syndrome patients requiring medical intervention either untreated or treated (i.e. under ACZ885, anakinra, or any other investigational IL-1 blocking therapy).~Exclusion Criteria:~* History of being immunocompromised, including a positive HIV at screening test result.~* No live vaccinations within 3 months prior to the start of the trial, during the trial, and up to 3 months following the last dose.~* History of significant medical conditions, which in the Investigator's opinion would exclude the patient from participating in this trial.~* History of recurrent and/or evidence of active bacterial, fungal, or viral infections.~* Positive tuberculin skin test at 48 to 72 hours after administration at the screening visit or within 2 months prior to the screening visit, according to national guidelines.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Part I, Part II-arm1, & Part III (Type: EXPERIMENTAL): None
- Part II - arm 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Between 21 and 70 years old.~* Documented to be HBsAg positive for ≥ 6 months.~* On any nucleos(t)ide analogue (lamivudine, adefovir, entecavir or tenofovir)for ≥ 1 year~* HBV DNA undetectable by RT PCR at screening~* Patient has agreed not to take any other investigational drug or systemic anti-viral, cytotoxic, corticosteroid, immunomodulatory agents or Chinese traditional remedies unless clinically indicated.~* Patient is able to give written consent prior to study start and to comply with the study requirements.~* Women of childbearing age must have a negative serum (ß-HCG) pregnancy test taken with 14 days of starting therapy~Exclusion Criteria:~* Evidence of decompensated liver disease or hepatocellular carcinoma.~* Have any of the following laboratory tests within 4 weeks of study entry:~* HIV antibody or HCV antibody or HDV antibody positivity~* Absolute neutrophil count \< 1.5 X 109/l or platelets \< 90 x 109/l or hemoglobin \< 13 g/dL for men or 12g/dL for women~* serum albumin \<35 g/l or serum bilirubin \> 30 mg/l~* creatinine \> 1.5 times upper limit of normal~* prothrombin time \> 1.5 times control, uncorrected by Vitamin K therapy.~* Any interferon, Immunomodulators, systemic cytotoxic agents, or systemic corticosteroids within 6 months before trial entry.~* Prolonged exposure to known hepatotoxins such as alcohol or drugs.~* History of clinically relevant psychiatric disease, seizures, central nervous system dysfunction, severe pre-existing cardiac, renal, hematological disease or medical illness that in the investigator's opinion might interfere with therapy.~* Malignant disease within 5 years of trial entry.~* Women who are pregnant and who are not practicing adequate birth control measures, or who are lactating

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Continued oral nucleos(t)ide therapy (Type: ACTIVE_COMPARATOR): Patients assigned to this arm will continue their nucleos(t) analogue
- Add on peg-interferon (Type: EXPERIMENTAL): Patients assigned to this arm will continue their existing nucleos(t)ide therapy and also be assigned peg-interferon alpha 2b 1.5mcg/kg sc weekly
- switch to peg-interferon (Type: EXPERIMENTAL): Patients assigned to this arm will stop their existing nucleos(t)ide therapy after one month overlap after starting peg-interferon alpha 2b 1.5mcg/kg sc weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LIraglutide and Beta-cell RepAir (LIBRA) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* men and women between the ages of 30 and 75 years inclusive~* physician-diagnosed type 2 diabetes of \</= 7 years duration~* negative for anti-GAD antibodies~* on 0-2 oral anti-diabetic medications~* A1c at screening between 5.5% and 9.0% inclusive, if on oral anti-diabetic medications, or between 6.0% and 10.0% inclusive, if not on oral anti-diabetic medications~Exclusion Criteria:~* use of insulin, GLP-1 agonist, or dipeptidyl peptidase-4 (DPP-4) inhibitor~* type 1 diabetes or secondary forms of diabetes~* major illness with life expectancy \< 5 years~* involvement in another study requiring drug therapy~* hypersensitivity to insulin, liraglutide, or metformin~* renal dysfunction~* hepatic dysfunction~* history of pancreatitis~* family or personal history of Multiple Endocrine Neoplasia type 2 (MEN-2) or familial medullary thyroid carcinoma~* personal history of non-familial medullary thyroid carcinoma~* malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy within the previous 5 years (with the exception of basal cell skin cancer)~* excessive alcohol consumption~* unwillingness to undergo multiple daily insulin injection therapy~* unwillingness to perform capillary blood glucose monitoring at least 4 times per day during intensive insulin therapy~* congestive heart failure~* pregnancy

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Smell on Mood and Physical Responses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults with a normal sense of smell~Exclusion Criteria:~* Treatment with medication that has immunological or endocrinological consequences~* Chronic health problems that affect immune or endocrine systems~* Allergy to perfume or cosmetics~* Problems with sense of smell~* Respiratory problems~* Smoker~* Current active asthma~* Use of psychoactive drugs or mood-altering medication~* History of anxiety disorder, major depression, bipolar disorder, schizophrenia, or other psychotic disorders~* History of chest pain or ventricular fibrillation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 44 Years
- Healthy Volunteers: t

Study Arms:
- Lavender (Type: EXPERIMENTAL): None
- Citrus (Type: EXPERIMENTAL): None
- Water (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of APD356 in the Treatment of Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or nonpregnant, nonlactating females aged 18-65 years (inclusive)~* Body mass index (BMI) of 30-45 kg/m2~* Non-smoker~* No concomitant medications other than hypertension medications (stable \> 90 days) and/or statins (stable \> 90 days)~* No past treatment with drugs associated with the development of pulmonary hypertension or cardiac valvular insufficiency~* No more than mild mitral valve regurgitation and absence of aortic valve regurgitation upon screening echocardiogram

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Child with T1DM for at least 1 year~* Age 10-19 years~* Have a Hgb A1C greater than or equal to 9.0% but less than or equal 13.9% for at least 6 months.~* School must have a school nurse~Exclusion Criteria:~* Child who has Type 2 diabetes~* Subject receiving home schooling

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parent/legal acceptable representatives of children or the adult participants are willing and able to understand the protocol requirements and provide informed consent signed~* Participant is considered to be in good health including the body and mental status on the basis of reported medical history and limited physical examination and live in local ≥ 12 months~* Participant body temperature ≤ 37.0℃~* Participant without preventive inoculation of rabies vaccine(only limited in immunogenicity subgroup)~Exclusion Criteria:~* Three-level exposure~* Known allergy to any constituent of the vaccine~* Reported the history of allergies, convulsions, epilepsy, mental illness and brain disease and clear serious systemic reaction~* Known bleeding disorder or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth~* Participation in any other interventional clinical trial~* An acute illness with or without fever (temperature \> 37.0℃) in the latest week preceding enrollment in the trial~* Inoculated other vaccines, immunoglobulin or investigational drugs within 4 weeks prior to participation in the study~* Reported clearly the infection of the upper respiratory tract with 6 months Clinical Manifestation of Metabolic, blood system, lungs, heart, the gastrointestinal tract, nervous system, kidneys, urinary system, endocrine, liver disease or malignant tumor~* Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the vaccine

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Zagreb2-1-1 (Type: EXPERIMENTAL): Injection on day 0、7、21
- Essen (Type: ACTIVE_COMPARATOR): Injection on day 0、3、7、14、28

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dutch Acute HCV in HIV Study (DAHHS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Documented recent HCV genotype 1 infection (≤26 weeks old at the time of the baseline visit) according to definition mentioned below.~2. Plan to start a Standard Of Care therapy for acute HCV consisting of 24 weeks of Peginterferon + Ribavirin. HCV RNA plasma viral load at screening \>1000 IU/ml.~3. A previously performed HCV RNA plasma measurement can be used for screening if \<4 weeks old.~4. On HAART at the time of screening.~5. Minimum age 18 years.~Exclusion Criteria:~1. Disallowed co-medication that cannot be stopped or replaced: Several potentially life-threatening drug-drug interactions (DDI) are possible when boceprevir is combined with other drugs. Therefore ALL co-medication, including over-the-counter drugs should be checked for potential DDI with DDI table in the Dutch summary of product characteristics (SPC, appendix A). If the co-medication is not mentioned in the SPC DDI table, www.HCV-druginteractions.org should be used.~2. Contraindications for the use of full dose of peginterferon alpha-2b or ribavirin: neutrophils \<0,75×109/l or thrombocytes \< 100.000×109/l or a Hb \<6.2mmol/L, creatinine clearance \<50ml/min).~3. History of liver cirrhosis or \>F1 fibrosis on fibroscan. Inclusion of patients with a chronic well-controlled HBV (HBV-DNA below the limit of detection) with tenofovir, lamivudine or emtricitabine therapy is allowed if fibroscan excludes \>F1 fibrosis. Fibroscan reports \<2 years old can be used for screening. Fibroscan is not required for other patients at screening.~4. HAART was started \<4 weeks before baseline visit.~5. Inability to switch to a HAART regimen consisting of 2 nucleoside/tide reverse transcriptase inhibitors + Raltegravir (Isentress®) 400mg BID or rilpivirine 25mg QD or atazanavir (Reyataz®) 300mg QD + ritonavir (Norvir®) 100mg QD.~6. Patient that virologically failed HAART in the past

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Boceprevir, peginterferon ribavirin (Type: EXPERIMENTAL): All patients were intended to be treated in the 12 week peginterferon, ribavirin and boceprevir arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is ≥ 18 years of age.~* Patient has a panel reactive antibody (PRA) ≥ 70% at any time prior to screening.~* Patient is considered compliant and intends to be available for a minimum follow-up study period of 1 year.~* Patient must be vaccinated against Neisseria meningitides at least 2 weeks prior to receiving treatment therapy or receive appropriate antibiotic prophylaxis for the duration of eculizumab treatment if timely vaccination could not be achieved prior to transplantation.~* Voluntary written informed consent must be obtained before performance of any study-related procedure not considered routine medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.~* Female subject is either post-menopausal or surgically sterilized or willing to use two acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and for up to 2 months after the last dose of study medication.~Exclusion Criteria:~* Donor or recipient age is \< 18 years or \> 75 years.~* Cold ischemia time is \> 6 hours.~* Current clinical, radiographic, or laboratory evidence of active or latent tuberculosis (TB), as determined by local standard of care.~* History of active TB within the last 2 years, even if treated.~* History of active TB greater than 2 years ago, unless there is documentation of adequate treatment according to locally accepted clinical practice.~(Note: Patients at risk of TB reactivation preclude administration of conventional immunosuppression, as determined by the study investigator and based upon appropriate evaluation).~* Receipt of desensitization treatment with rituximab less than 2 weeks prior to therapy and cluster of differentiation antigen 20 (CD20) count \>2%.~* Receipt of a live vaccine within 4 weeks prior to study entry.~* Patients with current or recent severe systemic infections within the 2 weeks prior to transplantation.~* Prior history of splenectomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): Administration of Eculizumab to heart transplant recipients at Cedars Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, for the prevention of antibody-mediated rejection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Male Hormonal Contraceptive Development-ACY-5

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males between 18-55~* In good general health~* With normal sperm counts~* Willing to use an acceptable form of contraception~Exclusion Criteria:~* Men in poor health~* Significant chronic or acute medical illness~* Skin conditions that might interfere with or be exacerbated by testosterone gel~* Known history of alcohol, illicit drug or anabolic steroid abuse~* Abnormal reproductive function~* Participation in a long-term male contraceptive study within past three months

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Testosterone (T) gel for 6 months + DMPA (injected into muscle once)on Day 0 and at Month 3
- 2 (Type: ACTIVE_COMPARATOR): Testosterone (T) gel for 6 months + DMPA (injected into muscle on Day 0 \& at month 3) + Acyline (SQ) every two weeks for the first 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nexium RESPONSE Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients attending general practice due to symptoms suggestive of acid related disease and, according to normal routine, the GP would prescribe an acid-inhibiting agent~Exclusion Criteria:~* Alarm symptoms~* Pregnancy~* Contraindications to Nexium

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer)~Exclusion Criteria:~* Diagnosis of myasthenia gravis, Eaton-Lambert Syndrome, or amyotrophic lateral sclerosis~* Headache attributed to another disorder~* Infection or skin disorder at injection sites~* Previous treatment with botulinum toxin of any serotype for any reason~* Anticipated need for botulinum toxin of any type for any reason during the course of the study~* Previous participation in any botulinum toxin clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BOTOX® (Type: EXPERIMENTAL): Participants received 155 U of onabotulinumtoxinA (BOTOX®) approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete